Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer-Reference-Cited by-同舟云学术

Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer

Published:2023-03 Issue:10 Volume:19 Page:727-736
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Kahraman Seda¹^ORCID,Erul Enes²^ORCID,Seyyar Mustafa³,Gumusay Ozge⁴,Bayram Ertugrul⁵,Demirel Burcin Cakan⁶,Acar Omer⁷,Aksoy Sercan²,Baytemur Naziyet Kose⁸,Sahin Elif³,Cabuk Devrim³,Basaran Gul⁴,Paydas Semra⁵^ORCID,Yaren Arzu⁶,Guven Deniz Can²^ORCID,Erdogan Atike Pinar⁷,Demirci Umut⁸,Yasar Alper⁹,Bayoglu İbrahim Vedat⁹,Hizal Mutlu¹^ORCID,Gulbagci Burcu¹⁰,Paksoy Nail¹¹,Davarci Sena Ece¹²,Yilmaz Funda¹³,Dogan Ozlem¹⁴,Orhan Sibel Oyucu¹⁵,Kayikcioglu Erkan¹⁶^ORCID,Aytac Ali¹⁷,Keskinkilic Merve¹⁸,Mocan Eda Eylemer¹⁹^ORCID,Unal Olcun Umit²⁰,Aydin Esra²¹,Yucel Hakan²²,Isik Deniz²³,Eren Onder²⁴,Uluc Basak Oyan⁴,Ozcelik Melike²⁵,Hacibekiroglu Ilhan¹⁰,Aydiner Adnan¹¹,Demir Hacer¹²,Oksuzoglu Berna¹³,Cilbir Ebru¹⁴,Cubukcu Erdem¹⁵,Cetin Bulent¹⁶,Oktay Esin¹⁷,Erol Cihan¹^ORCID,Okutur Sadi Kerem²⁶,Yildirim Nilgun²⁷,Alkan Ali²⁸^ORCID,Selcukbiricik Fatih²⁹,Aksoy Asude³⁰,Karakas Yusuf³¹,Ozkanli Gulhan³²,Duman Berna Bozkurt³³^ORCID,Aydin Dincer³⁴,Dulgar Ozgecan³⁵,Er Muhammed Muhiddin³⁶,Teker Fatih²²,Yavuzsen Tugba¹⁸,Aykan Musa Baris³⁷,Inal Ali³⁸,Iriagac Yakup³⁹,Kalkan Nurhan Onal⁴⁰,Keser Murat²⁰,Sakalar Teoman³⁵,Menekse Serkan⁴¹,Kut Engin⁴¹,Bilgin Burak⁴²,Karaoglanoglu Muge⁴³,Sunar Veli⁴⁴,Ozdemir Ozlem⁴⁵,Turhal Nazim Serdar⁴⁶,Karadurmus Nuri³⁷,Yalcin Bulent¹,Nahit Sendur Mehmet Ali¹

Affiliation:

1. Department of Medical Oncology, Ankara Yildirim Beyazit University, Ankara City Hospital, Ankara, 06800, Turkey

2. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, 06590, Turkey

3. Department of Medical Oncology, Kocaeli University Medical Faculty Hospital, Kocaeli, 41000, Turkey

4. Department of Medical Oncology, Acibadem University, School of Medicine, Istanbul, 34750, Turkey

5. Department of Medical Oncology, Cukurova University, Adana, 01330, Turkey

6. Department of Medical Oncology, Pamukkale University Hospital, Denizli, 20160, Turkey

7. Department of Medical Oncology, Manisa Celal Bayar University Hospital, Mersin, 45120, Turkey

8. Department of Medical Oncology, Ankara Memorial Hospital, Ankara, 06520, Turkey

9. Department of Medical Oncology, Marmara University Pendik Research & Application Hospital, Istanbul, 34899, Turkey

10. Department of Medical Oncology, Sakarya University School of Medicine, Sakarya, 54187, Turkey

11. Department of Medical Oncology, Istanbul University, Istanbul, 34093, Turkey

12. Department of Medical Oncology, Afyonkarahisar Health Sciences University, Afyonkarahisar, 03200, Turkey

13. Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training & Research Hospital, Ankara, 06200, Turkey

14. Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, 06170, Turkey

15. Department of Medical Oncology, Uludag University, Bursa, 16059, Turkey

16. Department of Medical Oncology, Suleyman Demirel University, Isparta, 32260, Turkey

17. Department of Medical Oncology, Aydin Adnan Menderes University Training & Research Hospital, Aydin, 09100, Turkey

18. Department of Medical Oncology, Dokuz Eylül University Research & Application Hospital, Izmir, 35340, Turkey

19. Department Of Medical Oncology, Ankara University, Ankara, 06080, Turkey

20. Department of Medical Oncology, Tepecik Training & Research Hospital, Izmir, 35180, Turkey

21. Department of Medical Oncology, Recep Tayyip Erdoğan University Training & Research Hospital, Rize, 53020, Turkey

22. Department of Medical Oncology, Gaziantep University, Gaziantep, 27580, Turkey

23. Department of Medical Oncology, Kocaeli Medical Park Hospital, Kocaeli, 41140, Turkey

24. Department of Medical Oncology, Selcuk University Medical Faculty Hospital, Konya, 42250, Turkey

25. Department of Medical Oncology, Umraniye Training & Research Hospital, Istanbul, 34764, Turkey

26. Department of Medical Oncology, Istanbul Arel University, Bahcelievler Memorial Hospital, Istanbul, 34537, Turkey

27. Department of Medical Oncology, Firat University Hospital, Elazig, 23200, Turkey

28. Department of Medical Oncology, Muğla Sıtkı Koçman University Training & Research Hospital, Mugla, 48000, Turkey

29. Department of Medical Oncology, Koç University Hospital, Istanbul, 34010, Turkey

30. Department of Medical Oncology, Elazig Fethi Sekin City Hospital, Elazig, 23280, Turkey

31. Department of Medical Oncology, Acıbadem Bodrum Hospital, Mugla, 48420, Turkey

32. Department of Medical Oncology, Canakkale Onsekiz Mart University Research & Practice Hospital, Canakkale, 17100, Turkey

33. Department of Medical Oncology, Adana City Training & Research Hospital, Adana, 01230, Turkey

34. Department of Medical Oncology, Kocaeli Derince Training & Research Hospital, Kocaeli, 41310, Turkey

35. Department of Medical Oncology, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras, 46050, Turkey

36. Department of Medical Oncology, Necmettin Erbakan University Meram Medical Faculty Hospital, Konya, 42080, Turkey

37. Department of Medical Oncology, Gulhane Training & Research Hospital, Ankara, 06010, Turkey

38. Department of Medical Oncology, Mersin City Hospital, Mersin, 96015, Turkey

39. Department of Medical Oncology, Namik Kemal University Health Application & Research Hospital, Tekirdag, 59030, Turkey

40. Department of Medical Oncology, Van Yüzüncü Yıl University Dursun Odabas Hospital, Van, 65090, Turkey

41. Department of Medical Oncology, Manisa City Hospital, Manisa, 45040, Turkey

42. Department of Medical Oncology, Konya City Hospital, Konya, 42020, Turkey

43. Department of Medical Oncology, Ordu State Hospital, Ordu, 52200, Turkey

44. Department of Medical Oncology, Aydin Ataturk State Hospital, Aydin, 09020, Turkey

45. Department of Medical Oncology, Izmir Bozyaka Training & Research Hospital, Izmir, 35170, Turkey

46. Department of Medical Oncology, Anadolu Medical Center, Istanbul, 34758, Turkey

Abstract

Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2022-1287

Reference19 articles.

1. Cancer statistics, 2022

2. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)

3. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E

4. Targeting CDK4 and CDK6: From Discovery to Therapy

5. Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR + /HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand;BMC Cancer;2024-08-16

2. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study;Breast Cancer Research and Treatment;2024-08-09

3. Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials;Oncology and Therapy;2024-08-02

4. Effectiveness of cyclin-dependent kinase 4 and 6 inhibitors for the treatment of hormonesensitive HER2-negative metastatic breast cancer in first-line therapy: A systematic literature review;Tumors of female reproductive system;2024-05-17

5. Simultaneous quantification of four hormone therapy drugs by LC-MS/MS: Clinical applications in breast cancer patients;Journal of Pharmaceutical and Biomedical Analysis;2024-05